First National Corp MA ADV Reduces Position in Pfizer Inc. (NYSE:PFE)

First National Corp MA ADV reduced its stake in Pfizer Inc. (NYSE:PFE) by 11.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 8,181 shares of the biopharmaceutical company’s stock after selling 1,020 shares during the quarter. First National Corp MA ADV’s holdings in Pfizer were worth $237,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in the stock. Olistico Wealth LLC acquired a new stake in shares of Pfizer during the 2nd quarter worth about $25,000. MFA Wealth Advisors LLC acquired a new stake in Pfizer during the second quarter worth approximately $29,000. Quarry LP purchased a new stake in Pfizer in the 2nd quarter worth approximately $31,000. Creekmur Asset Management LLC acquired a new position in Pfizer in the 4th quarter valued at $32,000. Finally, Trivant Custom Portfolio Group LLC lifted its stake in shares of Pfizer by 100.0% during the 1st quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 600 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently weighed in on the company. StockNews.com upgraded Pfizer from a “hold” rating to a “buy” rating in a research report on Wednesday. Wells Fargo & Company increased their price objective on shares of Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 31st. Daiwa America upgraded shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $45.00 price target on shares of Pfizer in a research note on Thursday, October 3rd. Finally, Barclays boosted their price objective on shares of Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 31st. Eight equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Pfizer has a consensus rating of “Moderate Buy” and a consensus target price of $34.54.

Pfizer Stock Up 2.0 %

Shares of PFE traded up $0.57 during midday trading on Wednesday, hitting $29.75. The company had a trading volume of 8,627,175 shares, compared to its average volume of 37,266,738. The company has a quick ratio of 0.60, a current ratio of 0.86 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a 52 week low of $25.20 and a 52 week high of $33.92. The company’s 50 day moving average price is $29.09 and its 200 day moving average price is $28.35. The stock has a market cap of $168.58 billion, a price-to-earnings ratio of -486.33, a PEG ratio of 1.23 and a beta of 0.67.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, beating the consensus estimate of $0.46 by $0.14. The firm had revenue of $13.28 billion during the quarter, compared to analyst estimates of $12.96 billion. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. Pfizer’s quarterly revenue was up 2.1% on a year-over-year basis. During the same period in the previous year, the company earned $0.67 earnings per share. On average, equities research analysts predict that Pfizer Inc. will post 2.66 EPS for the current year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.